• Home (current)
  • La Società
    Chi siamo Soci collettivi Collaborazioni tecniche Bilancio societario
  • Sezioni Regionali
  • Convegni e Formazione
    Eventi SINU Altri eventi Eventi patrocinati
  • Newsletters
  • Cerca
  • Come iscriversi
  • Area Soci:
  • Registrati
  • Login
  • English version
  • Passa al contenuto principale

SINU

Società Italiana di Nutrizione Umana

EFSA – Sicurezza del latto‐N‐neotetraosio (LNnT) prodotto da ceppi derivati di E. coli BL21 come novel food

The EFSA NDA Panel was asked to deliver an opinion on the change in the production process and specifications of lacto‐N‐neotetraose (LNnT) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human‐identical milk oligosaccharide (HiMO) LNnT but also contains lactose, lacto‐N‐triose II (LNT II), para‐lacto‐N‐neo‐hexaose (para‐LNnH) and other related carbohydrates. The NF is produced by fermentation with two genetically modified strains of Escherichia coliBL21. LNnT when chemically synthesised or produced by microbial fermentation using another E. coli strain (K‐12) is already authorised and included in the EU list of NFs. This application is limited to a change in the manufacturing process and specifications while target population, uses and use levels and consequently the anticipated intake do not change. The information provided on the manufacturing process, including the absence of DNA from the producing microorganisms, composition, identity and specifications of the NF do not raise safety concerns. Particularly, the proposed changes in the specifications are limited to a slightly higher ash content and limits for the presence of yeast and moulds, while specifications for methanol and LNnT fructose isomer have been removed. Food supplements are not intended to be used if other foods with the added NF or breast milk for young children are consumed on the same day. The Panel concludes that lacto‐N‐neotetraose (LNnT) as a NF when produced by fermentation with two genetically modified strains of E. coliBL21 is safe under the proposed conditions of use.

Consulta il documento


HOME

LARN IV revisione
NMCD
Meno sale più salute
Come iscriversi
Questionari
Il Punto su…
Congresso SINU 2019
Documenti SINU

LA SOCIETA'

Chi siamo
Soci collettivi
Collaborazioni tecniche
Biancio societario

FORMAZIONE

Eventi SINU
Altri eventi
Eventi patrocinati

NEWS

In evidenza
News recenti

CONTATTI

Sezioni regionali
Gruppi di lavoro
Privacy policy

SEGRETERIA SINU

c/o BioMedia srl
via Libero Temolo 4
20126 Milano
02 45498282
02 45498199
info@sinu.it

Copyright © 2019 SINU - Tutti i diritti riservati.


Un progetto realizzato da: BioMedia srl.

Recupera password

Presto Disponibile